News
Polatuzumab Vedotin in the Treatment of NHL - News from the 25th EHA Congress
Polatuzumab vedotin (Polivy) is approved in the EU for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), for whom hematopoietic stem cell transplantation (HSCT) is not suitable. We provide an overview of the latest news regarding the role of this modern medicine in the therapy of non-Hodgkin's lymphomas (NHL), presented at the 25th Congress of the European Hematology Association (EHA), held virtually due to the pandemic situation.
How to Secure Diabetics with Atrial Fibrillation During PCI?
Optimal management of patients with atrial fibrillation undergoing percutaneous coronary…
Safety of Dabigatran in the Secondary Prevention of Venous Thromboembolism in Children
The direct thrombin inhibitor dabigatran is used by adult patients, among others, in the secondary…
Is It Better to Switch or Cycle in the Treatment of Rheumatoid Arthritis?
The ideal strategy for treating rheumatoid arthritis is still the subject of research. We therefore…
Remarkable Findings from the Subanalysis of the Efficacy and Safety of Teriflunomide in the Chinese Population with MS in Relation to Global Results
Teriflunomide, from the group of disease-modifying drugs (DMDs), intended for the treatment of…
Satisfaction of Patients Treated with Platinum Derivatives with Antiemetic Therapy
The fixed oral combination of netupitant with palonosetron (NEPA) is used for the prevention of…
Simple antiemetic prophylaxis for breast cancer patients treated with AC chemotherapy
The combination of an anthracycline cytostatic agent with cyclophosphamide (AC) is among the highly…
Observational Study of Pegylated rVIII Administration in Real Clinical Practice
A recently published article by American hematologists provided valuable information about the…
Cost-effectiveness in Bleeding Control for Acquired Hemophilia A
A pharmacoeconomic analysis showed favorable cost-effectiveness of activated prothrombin complex…
Comparison of Efficacy of Bisoprolol and Metoprolol ZOK in Patients with Mild to Moderate Hypertension – Results of the CREATIVE Study
Suppression of increased activity in the sympathoadrenal system is currently one of the main goals…
Conferences
News from the world of medicine
All conferences
Popular this week
- Intermittent Fasting May Carry Significant Health Risks
- How Compassion Fatigue Threatens Doctors and Other Healthcare Workers
- Good, Bad, or Ugly? What's the Deal with Eggs?
- Modern approaches enhancing the efficiency of antibiotic therapy in hospital practice
- Patient blood management – past, present and future